TY - JOUR
T1 - Familial combined hyperlipidemia
T2 - An overview of the underlying molecular mechanisms and therapeutic strategies
AU - Taghizadeh, Eskandar
AU - Esfehani, Reza Jafarzadeh
AU - Sahebkar, Amirhossein
AU - Parizadeh, Seyed Mostafa
AU - Rostami, Daryoush
AU - Mirinezhad, Mohammadreza
AU - Poursheikhani, Arash
AU - Mobarhan, Majid Ghayour
AU - Pasdar, Alireza
PY - 2019/9
Y1 - 2019/9
N2 - Among different types of dyslipidemia, familial combined hyperlipidemia (FCHL) is the most common genetic disorder, which is characterized by at least two different forms of lipid abnormalities: hypercholesterolemia and hypertriglyceridemia. FCHL is an important cause of cardiovascular diseases. FCHL is a heterogeneous condition linked with some metabolic defects that are closely associated with FCHL. These metabolic features include dysfunctional adipose tissue, delayed clearance of triglyceride‐rich lipoproteins, overproduction of very low‐density lipoprotein and hepatic lipids, and defect in the clearance of low‐density lipoprotein particles. There are also some genes associated with FCHL such as those affecting the metabolism and clearance of plasma lipoprotein particles. Due to the high prevalence of FCHL especially in cardiovascular patients, targeted treatment is ideal but this necessitates identification of the genetic background of patients. This review describes the metabolic pathways and associated genes that are implicated in FCHL pathogenesis. We also review existing and novel treatment options for FCHL. © 2019 IUBMB Life, 71(9):1221–1229, 2019
AB - Among different types of dyslipidemia, familial combined hyperlipidemia (FCHL) is the most common genetic disorder, which is characterized by at least two different forms of lipid abnormalities: hypercholesterolemia and hypertriglyceridemia. FCHL is an important cause of cardiovascular diseases. FCHL is a heterogeneous condition linked with some metabolic defects that are closely associated with FCHL. These metabolic features include dysfunctional adipose tissue, delayed clearance of triglyceride‐rich lipoproteins, overproduction of very low‐density lipoprotein and hepatic lipids, and defect in the clearance of low‐density lipoprotein particles. There are also some genes associated with FCHL such as those affecting the metabolism and clearance of plasma lipoprotein particles. Due to the high prevalence of FCHL especially in cardiovascular patients, targeted treatment is ideal but this necessitates identification of the genetic background of patients. This review describes the metabolic pathways and associated genes that are implicated in FCHL pathogenesis. We also review existing and novel treatment options for FCHL. © 2019 IUBMB Life, 71(9):1221–1229, 2019
KW - familial combined hyperlipidemia
KW - therapy
KW - molecular pathway
KW - hypercholesterolemia
KW - hypertriglyceridemia
U2 - 10.1002/iub.2073
DO - 10.1002/iub.2073
M3 - Article
SN - 1521-6543
VL - 71
SP - 1221
EP - 1229
JO - IUBMB life
JF - IUBMB life
IS - 9
ER -
